CER Daily Newsfeed

Podcast: What’s Behind Drug Pricing: The Hidden Role and Limits of Cost-Effectiveness Analysis

(3/31, Leerink Perspectives) comments “In this episode of Perspectives by the Leerink Center for Pharmacoeconomics, Melanie Whittington breaks down a fundamental—and increasingly consequential—question in health economics: what counts as value in cost-effectiveness analysis? For biotech leaders and investors, Mel cautions that this isn’t just an academic debate. The frameworks adopted by HTA bodies influence pricing, access, and ultimately, how innovation is rewarded.” Full

Longer-Term Real-World Data Needed to Compare Leqembi and Kisunla Opposing Treatment Strategies for Alzheimer’s, Says GlobalData

(3/31, GlobalData) comments “...Philippa Salter, Managing Neurology Analyst at GlobalData, comments: ‘While the data presented at AD/PD 2026 is important for showing clinicians, patients, and insurers that the continued use of Leqembi can provide ongoing benefit to patients without increasing safety concerns, it is not enough to conclude that Leqembi’s treatment strategy is superior to Kisunla’s. Questions remain over longer-term continued use of Leqembi in patients whose disease continues to remain stable rather than progressing, as well as the benefit versus the cost of continued treatment.’” Full

Video: The Role of Real-World Evidence in Psoriasis Treatment Decisions

(3/31, Benjamin Lockshin, MD, FAAD, The American Journal of Managed Care) “...[R]eal-world data offer a window into long-term outcomes that clinical trials, with their defined endpoints and follow-up periods, may not fully capture. For patients living with a chronic condition like psoriasis, understanding how a therapy performs over months and years of continuous use—rather than at a fixed primary endpoint—is critical to informed decision-making. Taken together, RWE helps bridge the gap between trial results and practical application, making it an indispensable tool for optimizing psoriasis care.” View Video

CTSI Annual Forum to Include Keynote on Clinical Research Engagement, Award Presentations

(4/1, University at Buffalo Clinical and Translational Science Institute) comments “...The 2026 forum is the first as CTSI Director for Sanjay Sethi, MD, SUNY Distinguished Professor, Senior Associate Dean for Clinical and Translational Research, Jacobs School of Medicine and Biomedical Sciences, who began serving in the role in October 2025. Among the event highlights, Sethi says, is the keynote from Tracy Yu-Ping Wang, MD, MHS, MSc, Chief Officer of Comparative Clinical Effectiveness Research (CER) for [PCORI]. ‘The Annual Forum is an important event on the CTSI calendar,’ Sethi says. ‘It offers an opportunity for investigators and staff to come together, in person, to discuss new findings and to consider the role researchers play in impacting public health. It will be particularly illuminating this year to hear more about PCORI from Dr. Wang.’” Full